The Senate health committee chair blocked President Donald Trump’s nominee to lead the National Science Foundation (NSF) on Wednesday, extending a leadership gap at the research funding agency amid ongoing controversy over the administration’s handling of science policy.
Senator Bill Cassidy, a Republican from Louisiana and chair of the committee, removed Jim O’Neill’s nomination from the agenda shortly after the panel convened. O’Neill, a former deputy to Health Secretary Robert F. Kennedy Jr., had been nominated months earlier but faced criticism from Cassidy and other members regarding his past conduct and independence.
Cassidy cited concerns that O’Neill “did not do enough to stand up for science” during his previous tenure in the administration and questioned his judgment following O’Neill’s involvement in the removal of Susan Monarez, the former director of the Centers for Disease Control and Prevention (CDC). O’Neill briefly served as acting CDC director after Monarez’s departure in August 2025 but was soon replaced and later nominated to lead the NSF amid a reorganization of the Department of Health and Human Services’ senior leadership.
Though Cassidy expressed personal regard for O’Neill, he emphasized that “this time requires leadership and fortitude and standing up for what is right.” Cassidy, a physician who is concluding his Senate term after losing a primary to a Trump-backed challenger, has faced criticism from public health advocates for supporting Kennedy’s confirmation.
The NSF has lacked a Senate-confirmed director since April 2025, when Sethuraman Panchanathan resigned amid the administration’s efforts to reshape the agency’s priorities. These efforts included attempts to cut funding for social sciences and withholding over $1 billion in appropriations approved by Congress. O’Neill’s background in venture capital and humanities, rather than scientific research, aligns with other Trump administration science appointees who lack traditional scientific credentials.
Separately, the White House withdrew another nominee, Dr. Heidi Overton, who was slated to become commissioner of the Food and Drug Administration (FDA). The withdrawal came on the eve of a critical committee vote, and sources indicated Overton, a domestic policy adviser linked to controversial health initiatives, did not have sufficient support among Republican senators to advance. Cassidy disputed this, asserting that she would have secured committee and Senate approval and would have “followed the science” in her role.
Both O’Neill’s stalled nomination and Overton’s withdrawal reflect ongoing turbulence in the administration’s scientific leadership amid broader debates over the direction of U.S. research and public health policy.
